A Phase 3 interventional study of NOV03 and Saline Solution in Dry Eye Disease, sponsored by Bausch & Lomb Incorporated. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.
Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one has the largest enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2020.
This study's enrollment of 620 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 216 across the 13 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
25 studies in Dry Eye Syndromes by Bausch Health Companies Inc.: 1 open now, 2 under way, none of them phase 3. Of 21 finished, 16 (76%) have results posted.
Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 3, and was the 17th registered.
Bausch Health Companies Inc.’s Dry Eye Syndromes studies by the year they started, since 2005.
1 of the studies testing perfluorohexyloctane in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679685Beijing Tongren HospitalPerfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bausch Health Companies Inc.’s 25 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject was excluded from participating in the study if he or she met any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100% perfluorohexyloctane 4 times daily (QID)
Drug: NOV03
0.6% sodium chloride solution 4 times daily (QID)
Drug: Saline Solution
100% perfluorohexyloctane
0.6% sodium chloride solution
Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total score of 15 points (sum of scores for each section).
Time frame: Assessed at Day 57
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57
Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").
Time frame: Assessed at Day 57
Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15
Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").
Time frame: Assessed at Day 15
Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total of 15 points (sum of scores for each section).
Time frame: Assessed at Day 15
Change From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57
Subjects will be asked about the severity of burning / stinging. Study staff will ask subjects to rate their ocular symptoms (both eyes simultaneously) due to ocular dryness by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no discomfort" and 100% corresponds to "maximal discomfort").
Time frame: Assessed at Day 57
Change From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum of 3 points in the central section.
Time frame: Assessed at Day 57
| Milestone | NOV03 | Saline Solution |
|---|---|---|
| Started | 311 | 309 |
| Completed | 302 | 296 |
| Not completed | 9 | 13 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Discontinued | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total score of 15 points (sum of scores for each section).
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57 | -2.3 ± 2.8 | -1.1 ± 2.9 |
Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 57 | -29.5 ± 28.6 | -19.0 ± 27.2 |
Study staff will ask participants to rate their severity of ocular dryness (both eyes simultaneously) by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no dryness" and 100% corresponds to "maximal dryness").
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Dryness Score (Visual Analogue Scale [VAS] Severity of Dryness) at Day 15 | -18.5 ± 23.6 | -10.5 ± 23.9 |
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum total of 15 points (sum of scores for each section).
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) at Day 15 | -1.9 ± 2.3 | -1.3 ± 2.4 |
Subjects will be asked about the severity of burning / stinging. Study staff will ask subjects to rate their ocular symptoms (both eyes simultaneously) due to ocular dryness by placing a vertical mark on a horizontal line to indicate the level of discomfort (0 corresponds to "no discomfort" and 100% corresponds to "maximal discomfort").
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Burning/Stinging (Visual Analogue Scale [VAS] Severity of Burning/Stinging) at Day 57 | -22.1 ± 27.5 | -13.7 ± 29.9 |
The National Eye Institute (NEI) scale relies on a chart that divides the cornea into five sections (central, superior, temporal, nasal, and inferior) and assigns a value from 0 (absent) to 3 (severe) to each section, based on the amount, size, and confluence of the punctate keratitis, for a maximum of 3 points in the central section.
| units on a scale | NOV03 | Saline Solution |
|---|---|---|
| Change From Baseline in Central Corneal Fluorescein Staining (NEI Scale) at Day 57 | -0.4 ± 0.8 | -0.1 ± 0.9 |
Collected over Assessed through the study, approximately 8 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NOV03 | 0/311 (0%) | 0/311 (0%) | 16/311 (5.1%) |
| Saline Solution | 0/309 (0%) | 0/309 (0%) | 19/309 (6.1%) |
| Event | NOV03 | Saline Solution |
|---|---|---|
| Eye disorderEye disorders | 16/311 | 16/309 |
| HyperaemiaVascular disorders | 0/311 | 3/309 |
| Age, Continuous(years) | NOV03 | Saline Solution | Total |
|---|---|---|---|
| Mean | 53.3 ± 17.38 | 53.8 ± 16.26 | 53.6 ± 16.82 |
| Sex: Female, Male(Participants) | NOV03 | Saline Solution | Total |
|---|---|---|---|
| Female | 250 | 238 | 488 |
| Male | 61 | 71 | 132 |
| Ethnicity (NIH/OMB)(Participants) | NOV03 | Saline Solution | Total |
|---|---|---|---|
| Hispanic or Latino | 63 | 65 | 128 |
| Not Hispanic or Latino | 248 | 244 | 492 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2020 to primary completion in Aug 2021, 9 months.
Results were first posted in Aug 2024, 2 years 11 months after primary completion. A results delay was requested in May 2022.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 9 months is close to that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perfluorohexyloctane